IQVIA Holdings Inc IQV reported Q3 sales of $3.74 billion, up 4.9% Y/Y on a reported basis and 4.1% at constant currency (CC), missing the consensus of $3.78 billion.
IQVIA reported Q3 adjusted EPS of $2.49, beating the consensus of $2.44.
Technology & Analytics Solutions revenue increased 2.2% (0.9% CC) to $1.43 billion.
Research & Development Solutions (R&DS) sales reached $2.12 billion, +7.2% (6.4% CC).
Contract Sales & Medical Solutions revenue was flat on a reported basis (up 4.9% at CC) to $183 million.
As of September 30, 2023, R&DS contracted backlog, including reimbursed expenses, was $28.8 billion, growing 11.7% year-over-year and 10.5% at constant currency.
The company expects approximately $7.4 billion of this backlog to convert to revenue in the next twelve months. The third-quarter book-to-bill ratio was 1.24x.
FY23 Guidance: The company updated its full-year guidance to reflect slower growth in the Technology & Analytics Solutions segment and the impact of the strengthening US dollar.
IQVIA forecasts FY23 adjusted EPS of $10.16-$10.23 versus prior guidance of $10.20-$10.45 and consensus Of $10.29.
The company sees FY23 revenue of $14.885-$14.92 billion compared to the prior guidance of $15.05-$15.175 billion and consensus of $15.12 billion.
Q4 FY23 Guidance: IQVIA anticipates revenue of $3.769-$3.804 billion and adjusted EPS of $2.79-$2.86 compared to the consensus of $3.96 billion and $2.94, respectively.
Price Action: IQV shares are down 4.98% at $171.82 on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.